If you have taken Zyprexa and you have suffered from a stroke you may be entitled to compensation.

Zyprexa is the brand name for Olanzapine, a thienobenzodiazepine. It is considered an “atypical” antipsychotic medication used to treat Schizophrenia and Bipolar Mania. Approved by the Food and Drug Administration (FDA) in 1996, it is thought that Zyprexa works by decreasing the effects of two chemical messengers in the brain, serotonin and dopamine.

For millions of people, prescription drugs are necessary to health and even survival. Yet, the very drugs designed to help people may cause adverse reactions that range from illness to disability to death. As recently as April 11, 2005 the FDA issued an alert advising health care providers, patients, and patient caregivers to safety issues regarding Zyprexa.

In February of 2004, Zyprexa drug maker, Eli Lilly and Company, notified doctors and psychiatrists that elderly patients with dementia face an increased risk of stroke with Zyprexa treatment. While not approved for use in elderly dementia patients, or for anxiety or depression, physicians still prescribe the drug on an “off-label” basis. Off-label use refers to the practice of marketing or prescribing a drug in a different dose, for a longer period of time, or for a different medical condition than approved by the FDA.

In the April 2005 announcement, the FDA asked manufacturers of Atypical Antipsychotic Drugs, including Zyprexa, to include a Boxed Warning in their product’s label that describes the risks and note that these drugs are not approved for “off-label” indications. Some estimates indicate that up to 75% of the 12 million patients who have been prescribed Zyprexa are not sufferers of Schizophrenia and Bipolar Mania, and have been prescribed Zyprexa "off-label".

Please consult your physician before discontinuing any medication.

Brown & Crouppen is backed by a team of lawyers who understand that large corporations and insurance companies must work to minimize liability in defective drugs and product claims to stay in business. A few of our attorney’s owe their unique perspective on product liability cases based on their previous work defending the large insurance companies that they litigate today. This experience gives our counselors the advantage of an in-depth understanding of how these large corporations work and how to work with them.

Brown & Crouppen has been building a reputation for success with personal injury clients for over 25 years. Today, we are one of mid-America’s largest personal injury law firms with over 70 legal professionals and five offices throughout Missouri and Illinois. A large area of our concentration is dangerous drug litigation involving manufacturers and suppliers of unsafe drugs and products.  If you have been injured by a dangerous drug, the manufacturer may have failed in its duty to design, make, inspect and label the product appropriately.

You can count on the lawyers of Brown & Crouppen for top-notch legal skills and our commitment to making the justice system work for our clients. If you have legal concerns and would like to benefit from the support of a strong team of legal professionals, please contact us online or call our office today at Toll-Free: 866-991-4700.

ZYPREXA NEWS & LAWYER UPDATES

Uncertainty was driver in Zyprexa deal
Indianapolis Star, IN -Jun 11, 2005
... on 8,000 claims of damages over the company's top-selling drug Zyprexa, as both sides saw the value of avoiding prolonged litigation that was full of ...

Lilly to Pay $690M to Settle Zyprexa Case
MSN Money -Jun 9, 2005
... $690 million to settle claims from an estimated 8,000 people who claim the company did not properly list risks associated with its anti-psychosis drug Zyprexa....